Screen4Rare is a multi-stakeholder platform launched by the International Patient Organisation for Primary Immunodeficiencies (IPOPI), the International Society for Neonatal Screening (ISNS), and the European Society for Immunodeficiencies (ESID) aiming to exchange knowledge and best practices on NBS for rare diseases.
The group’s ultimate objective is, through policy engagement, to work towards ensuring that all babies can have equitable access to newborn screening; a life-saving tool for conditions such as SCID.
Company Details
- Industry
- Health And Human Services
- NAICS
-
Administration of Human Resource ProgramsAdministration of Veterans' Affairs
- Website
- https://screen4rare.org/
- Competitors
- National Urea Cycle Disorders Foundation, Institute for Genomics Education, Workforce & Leadership at Sarah Lawrence College, STREP, IPOPI - International Patient Organisation for Primary Immunodeficiencies, VERITY, Department of Genetics and Genomic Sciences at Mount Sinai, Queen Mary University Genome Centre, AMPLIFY, International Society for Neonatal Screening, Zinexts Life Science Corp..
Screen4rare Questions
Screen4Rare's website is https://screen4rare.org/
Screen4Rare's LinkedIn profile is https://www.linkedin.com/company/screen4rare
Screen4Rare's industry is
Health and Human Services
Screen4Rare's top competitors are
National Urea Cycle Disorders Foundation,
Institute For Genomics Education, Workforce & Leadership At Sarah Lawrence College,
Strep,
Ipopi - International Patient Organisation For Primary Immunodeficiencies,
Verity,
Department Of Genetics And Genomic Sciences At Mount Sinai,
Queen Mary University Genome Centre,
Amplify,
International Society For Neonatal Screening,
Zinexts Life Science Corp..
Screen4Rare's categories are Health and Human Services
